









Markets
/
Stocks
/
nasdaq-tern
/

Terns Pharmaceuticals Inc

TERN

14.030USD

+5.770+69.85%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

1.23BMarket Cap

LossP/E TTM



Terns Pharmaceuticals Inc

14.030

+5.770+69.85%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Terns Pharmaceuticals Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Terns Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

214 / 501

Overall Ranking

382 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

15.827

Target Price

+91.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Terns Pharmaceuticals Inc Highlights

StrengthsRisks

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -7.78, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 91.38M shares, decreasing 20.00% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 73.69K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Terns Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.70, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -7.78, which is -76.16% below the recent high of -1.85 and -18.77% above the recent low of -9.24.

Score

Industry at a Glance

Previous score

6.70

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 214/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Terns Pharmaceuticals Inc is 15.00, with a high of 28.00 and a low of 7.44.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

15.827

Target Price

+91.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Terns Pharmaceuticals Inc

TERN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 7.11, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 9.07 and the support level at 7.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.79

Change

0.32

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(5)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.086

Neutral

RSI(14)

53.280

Neutral

STOCH(KDJ)(9,3,3)

63.977

Neutral

ATR(14)

0.683

High Vlolatility

CCI(14)

7.457

Neutral

Williams %R

37.702

Buy

TRIX(12,20)

0.190

Sell

StochRSI(14)

37.654

Neutral

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

8.218

Buy

MA10

8.124

Buy

MA20

8.218

Buy

MA50

7.746

Buy

MA100

6.479

Buy

MA200

4.943

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 104.42%, representing a quarter-over-quarter increase of 3.74%. The largest institutional shareholder is The Vanguard, holding a total of 4.31M shares, representing 4.92% of shares outstanding, with 8.01% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Soleus Capital Management, L.P.

8.17M

OrbiMed Advisors, LLC

7.56M

Deep Track Capital LP

7.50M

+34.40%

Vivo Capital, LLC

6.90M

Morgan Stanley & Co. LLC

6.26M

+1.70%

BlackRock Institutional Trust Company, N.A.

4.98M

-2.74%

Commodore Capital LP

4.65M

The Vanguard Group, Inc.

Star Investors

4.31M

+3.71%

Citadel Advisors LLC

3.90M

-0.23%

Schonfeld Strategic Advisors LLC

3.05M

-20.68%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -0.03. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.